All News
RheumNow Eular 2023 Daily Recap Series https://t.co/ZJd3mSBcau
Dr. John Cush RheumNow ( View Tweet)
AOSD: Young vs. Elderly Onset
AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
https://t.co/PPI1fvwLAf https://t.co/qMXMsbpwl3
Links:
Dr. John Cush RheumNow ( View Tweet)
Top Influencers of #EULAR2023 đ @eular_org @EMEUNET @RheumNow @ARD_BMJ @drdavidliew @Janetbirdope https://t.co/uUJM6tW824 via @symplur
Alina DIMA drALINAdima ( View Tweet)
Wasnât following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T, including meeting highlights by Christian Dejaco.
Both look pretty exciting - the longer the sustained remission with CAR-T, the more it looks like maybe the real deal @RheumNow https://t.co/oKzb8ojTcz
David Liew drdavidliew ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on YouTube, Twitter and LinkedIn. https://t.co/i8rm5t8mFS
Dr. John Cush RheumNow ( View Tweet)
RheumNowâs expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.co/VHxtsB7ZsA
Bella Mehta bella_mehta ( View Tweet)
Adherence to TNFi follows different trajectories
Cluster 1: âmoderate then highâ 51%
Cluster 2: âmoderate then lowâ 20%
Cluster 3: âlow adherence, to discontinuationâ 18%
Cluster 4: âlow then high adherenceâ 11%
Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl
Aurelie Najm AurelieRheumo ( View Tweet)
@eular_org recommendations session #EULAR2023 - and the first recommendation is one Iâm so glad is up front:
Adult Onset Stillâs Disease (AOSD) and Systemic JIA (sJIA) are the same disease.
If anything, itâs the really young sJIA (<18 months old) which is different @RheumNow https://t.co/OCDeeNtNoR
David Liew drdavidliew ( View Tweet)
@eular_org recommendation for AOSD/sJIA:
An IL-1 or IL-6 inhibitor should be initiated as early as possible when the diagnosis is established
#EULAR2023 @RheumNow https://t.co/xNUdpGDxb9
David Liew drdavidliew ( View Tweet)
#EULAR2023 #POS1156 Previous case series reported ~9% de novo nephritis in #SLE pts treated with belimumab for non-renal lupus. Post-hoc analysis of 5 BEL Non-LN RCTs showed 8% had de novo LN. Risk increased in Asians but lowered with low dose BEL or s/c form @RheumNow https://t.co/GqAr3tppWh
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
One new overarching principle for @eular_org PsA recommendations:
âThe choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profileâ
Wonder what triggered that
#EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za
David Liew drdavidliew ( View Tweet)
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Dr. Antoni Chan synovialjoints ( View Tweet)
New 2023 @eular_org SLE recommendations
Key changes, in response to evidence:
- more caution re: steroids
- biologics earlier
- combo therapy (BEL or CNI/VCS) considered for lupus nephritis
#EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
David Liew drdavidliew ( View Tweet)
Key points from #EULAR2023 on how to manage SLE
@RheumNow https://t.co/vJy7Cg7w8N
David Liew drdavidliew ( View Tweet)
Late Breaker - EULAR 2023 update on imaging of large vessel vasculitis. Ultrasound is now recommended as first line imaging test in all patients with suspected GCA, and axillary arteries should be in the standard examination, Dejaco C et al, Abst#LB0009, #EULAR2023 @RheumNow https://t.co/ya41nJG6qK
Dr. Antoni Chan synovialjoints ( View Tweet)
#ClinicalPearl This is cool - think of SGLT2 for #lupus #nephritis? presented at #SLE recommendations âŠ@RheumNowâ© #EULAR2023 âŠ@eular_orgâ© https://t.co/8mbNt2n64v
Janet Pope Janetbirdope ( View Tweet)
#SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends @RheumNow #EULAR2023 https://t.co/Ylnnl3pHOK
Janet Pope Janetbirdope ( View Tweet)
Late Breaker - Cardiorespiratory fitness increased in patients with IJD after 12 weeks of supervised
HIIT and effect maintained at 6 months. No significant differences in pain and fatigue vs control. HIIT is a viable intervention Norden K Abst#LB0007 #EULAR2023 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)